Mibavademab

DRUG5 trials

Sponsors

Eli Lilly and Company, Regeneron Pharmaceuticals

Conditions

Functional Hypothalamic Amenorrhea (FHA)Generalized LipodystrophyMonogenic ObesityObesity

Phase 2

A Study of Tirzepatide (LY3298176) Plus Mibavademab Compared With Tirzepatide Alone in Adult Participants With Obesity

CompletedNCT06373146

Eli Lilly and CompanyObesity

Start: 2024-04-24End: 2026-04-02Updated: 2026-05-06

A Study to Investigate Mibavademab in Adult Women With Functional Hypothalamic Amenorrhea

RecruitingNCT07235917

Regeneron PharmaceuticalsFunctional Hypothalamic Amenorrhea (FHA)

Start: 2026-03-11End: 2027-12-08Target: 34Updated: 2026-07-14

Phase 3

A Study of the Safety of Mibavademab in Pediatric and Adult Participants Switching From Metreleptin to Mibavademab for the Treatment of Generalized Lipodystrophy (GLD)

CompletedNCT06548100

Regeneron PharmaceuticalsGeneralized Lipodystrophy

Start: 2024-12-16End: 2026-07-09Updated: 2026-07-29

A Study Evaluating Mibavademab Treatment of Obesity Due to Leptin (LEP) Gene Mutations in Children, Adolescents and Adults

RecruitingNCT07220772

Regeneron PharmaceuticalsMonogenic Obesity

Start: 2026-02-09End: 2028-04-21Target: 4Updated: 2026-03-10

Efficacy and Safety of Mibavademab in Adult and Pediatric Patients With Generalized Lipodystrophy

RecruitingNCT07220785

Regeneron PharmaceuticalsGeneralized Lipodystrophy

Start: 2026-03-13End: 2028-09-08Target: 28Updated: 2026-09-11